Pathology of Graft vs. Host Disease

Pathology of Graft vs

Editors: Cecilia C. S. Yeung, Howard M. Shulman


In 45 years, HSCT has emerged from a last-ditch experimental effort to cure hematologic malignancies into an established treatment with hundreds of transplant centers throughout the world. Despite the numerous technological advances leading to successful outcomes, GVHD with its associated immunodeficiency and infectious vulnerability remains the leading cause of non-relapse mortality.

Leave a Reply

Your email address will not be published. Required fields are marked *